Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol Myers Squibb, Canada

---
Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol Myers Squibb, Canada
Vote:
0 0
Previous Hycroft Appoints Michael Deal as Chief Operating Officer
Next HIGHWAY HOLDINGS REPORTS FISCAL FOURTH QUARTER AND FULL YEAR 2026 RESULTS

Related News

Harbour BioMed Enters into Global Strategic Collaboration and License Agreement with Bristol Myers Squibb to Discover and Develop Next-Generation Multi-Specific Antibodies

Fangzhou Inc. and Bristol Myers Squibb China Join Forces on a Strategic Alliance to Advance Internet Healthcare

Syngene International extends long-term research collaboration with Bristol Myers Squibb until 2035

Hengrui Pharma and Bristol Myers Squibb Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and Immunology

NYSE Content Update: Two MSCI Indexes to Begin Trading on NYSE Arca Options

Providence Therapeutics Announces Appointment of Leah Goodman to the Board of Directors

menu
menu